use of a compound with ep4 antagonistic activity or a pharmaceutically acceptable salt thereof, use of a compound of formula (i), (ii), (iii), (iv), (va) or (vb) or a pharmaceutically acceptable salt thereof, pharmaceutical composition for treating cartilage disease, method for treating cartilage disease in an animal subject, including a mammalian subject and compound of formula (i), (ii), (iii), (iv), ( va) or (vb) or a pharmaceutically acceptable salt thereof.
This invention relates to a compound with EP4 antagonistic activity, or a pharmaceutically acceptable salt with EP4 receptor antagonistic activities, which is useful in the treatment of cartilage disease. This invention also relates to a compound of formula (I), (II), (III), (IV), (Va) or (Vb), or a pharmaceutically acceptable salt thereof with EP4 receptor antagonistic activities, which is useful in the treatment of cartilage disease. This invention also relates to a pharmaceutical composition for the treatment of cartilage disease which comprises a therapeutically effective amount of a compound of formula (I), (II), (III), (IV), (Va) or (Vb), or a pharmaceutically acceptable salt thereof. Further this invention relates to a method for the treatment of cartilage disease in an animal subject including a mammalian subject, which comprises administering to the animal subject including a mammalian subject a compound of the formula (I), (II), (III), (IV), (Va) or (Vb), or a pharmaceutically acceptable salt thereof.
